X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
OATD-01 is an oral, small molecule inhibitor of chitinase-1 (CHIT1), which is being evaluated for the treatment of patients with acute pulmonary sarcoidosis.
Lead Product(s): OATD-01
Therapeutic Area: Immunology Product Name: OATD-01
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2024
Details:
OATD-01, is an oral, once-daily, first-in-class highly selective CHIT1 inhibitor for the treatment of pulmonary sarcoidosis. The inhibition of CHIT1 by OATD‑01 has been shown to reduce inflammation & fibrosis.
Lead Product(s): OATD-01
Therapeutic Area: Immunology Product Name: OATD-01
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2023
Details:
OATD-01, is an oral, once-daily, first-in-class highly selective CHIT1 inhibitor for the treatment of pulmonary sarcoidosis. The inhibition of CHIT1 by OATD‑01 has been shown to reduce inflammation & fibrosis.
Lead Product(s): OATD-01
Therapeutic Area: Immunology Product Name: OATD-01
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Galapagos
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2023
Details:
Molecure has regained (at no cost) the full and exclusive rights to the results of all research, pre-clinical and clinical development performed by Galapagos with OATD-01 over the course of the last 18 months.
Lead Product(s): OATD-01
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: OATD-01
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Galapagos
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 23, 2022
Details:
OncoArendi Therapeutics gains global development and commercialization rights of OncoArendi’s OATD-01. OATD-01 is a Phase 2-ready chitotriosidase/acidic mammalian chitinase inhibitor to treat Idiopathic pulmonary fibrosis and other diseases with a fibrotic component.
Lead Product(s): OATD-01
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: OATD-01
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Galapagos
Deal Size: $380.8 million Upfront Cash: $29.7 million
Deal Type: Licensing Agreement November 05, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
